 |
PDBsum entry 3dkb
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of a20, 2.5 angstrom
|
|
Structure:
|
 |
Tumor necrosis factor, alpha-induced protein 3. Chain: a, b, c, d, e, f. Fragment: unp residues 1-370. Synonym: DNA-binding protein a20, zinc finger protein a20. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: tnfaip3. Expressed in: escherichia coli.
|
|
Resolution:
|
 |
|
2.50Å
|
R-factor:
|
0.200
|
R-free:
|
0.246
|
|
|
Authors:
|
 |
S.-C.Lin,J.Y.Chung,Y.-C.Lo,H.Wu
|
Key ref:
|
 |
S.C.Lin
et al.
(2008).
Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20.
J Mol Biol,
376,
526-540.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
24-Jun-08
|
Release date:
|
08-Jul-08
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P21580
(TNAP3_HUMAN) -
Tumor necrosis factor alpha-induced protein 3 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
790 a.a.
352 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.3.2.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.4.19.12
- ubiquitinyl hydrolase 1.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Thiol-dependent hydrolysis of ester, thiolester, amide, peptide and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-residue protein attached to proteins as an intracellular targeting signal).
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
376:526-540
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20.
|
|
S.C.Lin,
J.Y.Chung,
B.Lamothe,
K.Rajashankar,
M.Lu,
Y.C.Lo,
A.Y.Lam,
B.G.Darnay,
H.Wu.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Nuclear factor kappaB (NF-kappaB) activation in tumor necrosis factor,
interleukin-1, and Toll-like receptor pathways requires Lys63-linked
nondegradative polyubiquitination. A20 is a specific feedback inhibitor of
NF-kappaB activation in these pathways that possesses dual ubiquitin-editing
functions. While the N-terminal domain of A20 is a deubiquitinating enzyme (DUB)
for Lys63-linked polyubiquitinated signaling mediators such as TRAF6 and RIP,
its C-terminal domain is a ubiquitin ligase (E3) for Lys48-linked degradative
polyubiquitination of the same substrates. To elucidate the molecular basis for
the DUB activity of A20, we determined its crystal structure and performed a
series of biochemical and cell biological studies. The structure reveals the
potential catalytic mechanism of A20, which may be significantly different from
papain-like cysteine proteases. Ubiquitin can be docked onto a conserved A20
surface; this interaction exhibits charge complementarity and no steric clash.
Surprisingly, A20 does not have specificity for Lys63-linked polyubiquitin
chains. Instead, it effectively removes Lys63-linked polyubiquitin chains from
TRAF6 without dissembling the chains themselves. Our studies suggest that A20
does not act as a general DUB but has the specificity for particular
polyubiquitinated substrates to assure its fidelity in regulating NF-kappaB
activation in the tumor necrosis factor, interleukin-1, and Toll-like receptor
pathways.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Fig. 4. The predicted interaction of A20 with ubiquitin. (a
and b) Mapping of conserved residues on the A20 surface. The
location of the active site is circled. (c) Ribbon diagram of
A20 with modeled ubiquitins. The locations of the ubiquitin
based on the HAUSP–ubiquitin and Yuh1–ubiquitin complexes
are shown in gray and orange, respectively. The location of the
ubiquitin after adjustment to avoid steric clash is shown in
yellow. (d) Surface presentation of A20 shown in complex with
the modeled ubiquitin in a ribbon diagram. The active site is
circled. (e) Electrostatic surface presentation of A20 shown in
complex with the modeled ubiquitin in a ribbon diagram. The
ubiquitin-binding site is mostly negatively charged. (f and g)
The model of the A20–ubiquitin complex shown with A20 in a
ribbon diagram and the ubiquitin in an electrostatic surface
representation. The positive electrostatic potential of the side
of ubiquitin in contact with A20 is shown. (h) The proposed
oxyanion hole construction of A20 by the main-chain amides of
Cys103, Gly101, and Asp100. The corresponding regions in Yuh1
and HAUSP are superimposed and shown.
|
 |
Figure 6.
Fig. 6. Structure-based mutational analyses. (a) Cleavage of
Lys48-linked polyubiquitin chains by wild-type and mutant A20.
(b) Cleavage of Lys48-linked diubiquitin by wild-type and mutant
A20. (c) Deubiquitination of Lys63-linked polyubiquitinated
GST-TRAF6 by wild-type and mutant A20. The left panel shows the
appearance of ubiquitin chains in the supernatant of glutathione
beads. The right panel shows the decrease in the
polyubiquitination of GST-TRAF6 bound to glutathione beads.
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by Elsevier:
J Mol Biol
(2008,
376,
526-540)
copyright 2008.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Ma,
and
B.A.Malynn
(2012).
A20: linking a complex regulator of ubiquitylation to immunity and human disease.
|
| |
Nat Rev Immunol,
12,
774-785.
|
 |
|
|
|
|
 |
J.D.Licchesi,
J.Mieszczanek,
T.E.Mevissen,
T.J.Rutherford,
M.Akutsu,
S.Virdee,
F.El Oualid,
J.W.Chin,
H.Ovaa,
M.Bienz,
and
D.Komander
(2012).
An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains.
|
| |
Nat Struct Mol Biol,
19,
62-71.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
O.W.Huang,
X.Ma,
J.Yin,
J.Flinders,
T.Maurer,
N.Kayagaki,
Q.Phung,
I.Bosanac,
D.Arnott,
V.M.Dixit,
S.G.Hymowitz,
M.A.Starovasnik,
and
A.G.Cochran
(2012).
Phosphorylation-dependent activity of the deubiquitinase DUBA.
|
| |
Nat Struct Mol Biol,
19,
171-175.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Grabbe,
K.Husnjak,
and
I.Dikic
(2011).
The spatial and temporal organization of ubiquitin networks.
|
| |
Nat Rev Mol Cell Biol,
12,
295-307.
|
 |
|
|
|
|
 |
C.Zheng,
Q.Yin,
and
H.Wu
(2011).
Structural studies of NF-κB signaling.
|
| |
Cell Res,
21,
183-195.
|
 |
|
|
|
|
 |
E.W.Harhaj,
and
V.M.Dixit
(2011).
Deubiquitinases in the regulation of NF-κB signaling.
|
| |
Cell Res,
21,
22-39.
|
 |
|
|
|
|
 |
T.W.James,
N.Frias-Staheli,
J.P.Bacik,
J.M.Levingston Macleod,
M.Khajehpour,
A.García-Sastre,
and
B.L.Mark
(2011).
Structural basis for the removal of ubiquitin and interferon-stimulated gene 15 by a viral ovarian tumor domain-containing protease.
|
| |
Proc Natl Acad Sci U S A,
108,
2222-2227.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
I.Bosanac,
I.E.Wertz,
B.Pan,
C.Yu,
S.Kusam,
C.Lam,
L.Phu,
Q.Phung,
B.Maurer,
D.Arnott,
D.S.Kirkpatrick,
V.M.Dixit,
and
S.G.Hymowitz
(2010).
Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling.
|
| |
Mol Cell,
40,
548-557.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.M.Kingeter,
and
B.C.Schaefer
(2010).
Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives?
|
| |
Cell Signal,
22,
9.
|
 |
|
|
|
|
 |
L.M.Staudt
(2010).
Oncogenic activation of NF-kappaB.
|
| |
Cold Spring Harb Perspect Biol,
2,
a000109.
|
 |
|
|
|
|
 |
N.Shembade,
and
E.Harhaj
(2010).
A20 inhibition of NFκB and inflammation: targeting E2:E3 ubiquitin enzyme complexes.
|
| |
Cell Cycle,
9,
2481-2482.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
and
I.E.Wertz
(2010).
A20: from ubiquitin editing to tumour suppression.
|
| |
Nat Rev Cancer,
10,
332-341.
|
 |
|
|
|
|
 |
A.Lake,
L.A.Shield,
P.Cordano,
D.T.Chui,
J.Osborne,
S.Crae,
K.S.Wilson,
S.Tosi,
S.J.Knight,
S.Gesk,
R.Siebert,
R.T.Hay,
and
R.F.Jarrett
(2009).
Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.
|
| |
Int J Cancer,
125,
1334-1342.
|
 |
|
|
|
|
 |
B.A.Beutler
(2009).
TLRs and innate immunity.
|
| |
Blood,
113,
1399-1407.
|
 |
|
|
|
|
 |
B.Coornaert,
I.Carpentier,
and
R.Beyaert
(2009).
A20: central gatekeeper in inflammation and immunity.
|
| |
J Biol Chem,
284,
8217-8221.
|
 |
|
|
|
|
 |
B.Skaug,
X.Jiang,
and
Z.J.Chen
(2009).
The role of ubiquitin in NF-kappaB regulatory pathways.
|
| |
Annu Rev Biochem,
78,
769-796.
|
 |
|
|
|
|
 |
D.Komander,
M.J.Clague,
and
S.Urbé
(2009).
Breaking the chains: structure and function of the deubiquitinases.
|
| |
Nat Rev Mol Cell Biol,
10,
550-563.
|
 |
|
|
|
|
 |
E.Chanudet,
H.Ye,
J.Ferry,
C.Bacon,
P.Adam,
H.Müller-Hermelink,
J.Radford,
S.Pileri,
K.Ichimura,
V.Collins,
R.Hamoudi,
A.Nicholson,
A.Wotherspoon,
P.Isaacson,
and
M.Du
(2009).
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands.
|
| |
J Pathol,
217,
420-430.
|
 |
|
|
|
|
 |
F.E.Reyes-Turcu,
and
K.D.Wilkinson
(2009).
Polyubiquitin binding and disassembly by deubiquitinating enzymes.
|
| |
Chem Rev,
109,
1495-1508.
|
 |
|
|
|
|
 |
F.E.Reyes-Turcu,
K.H.Ventii,
and
K.D.Wilkinson
(2009).
Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.
|
| |
Annu Rev Biochem,
78,
363-397.
|
 |
|
|
|
|
 |
F.Renner,
and
M.L.Schmitz
(2009).
Autoregulatory feedback loops terminating the NF-kappaB response.
|
| |
Trends Biochem Sci,
34,
128-135.
|
 |
|
|
|
|
 |
H.Eleftherohorinou,
V.Wright,
C.Hoggart,
A.L.Hartikainen,
M.R.Jarvelin,
D.Balding,
L.Coin,
and
M.Levin
(2009).
Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases.
|
| |
PLoS One,
4,
e8068.
|
 |
|
|
|
|
 |
H.Shinohara,
and
T.Kurosaki
(2009).
Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling.
|
| |
Immunol Rev,
232,
300-318.
|
 |
|
|
|
|
 |
J.Wang,
Y.Ouyang,
Y.Guner,
H.R.Ford,
and
A.V.Grishin
(2009).
Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes.
|
| |
J Immunol,
183,
1384-1392.
|
 |
|
|
|
|
 |
M.W.Popp,
K.Artavanis-Tsakonas,
and
H.L.Ploegh
(2009).
Substrate Filtering by the Active Site Crossover Loop in UCHL3 Revealed by Sortagging and Gain-of-function Mutations.
|
| |
J Biol Chem,
284,
3593-3602.
|
 |
|
|
|
|
 |
T.Wang,
L.Yin,
E.M.Cooper,
M.Y.Lai,
S.Dickey,
C.M.Pickart,
D.Fushman,
K.D.Wilkinson,
R.E.Cohen,
and
C.Wolberger
(2009).
Evidence for bidentate substrate binding as the basis for the K48 linkage specificity of otubain 1.
|
| |
J Mol Biol,
386,
1011-1023.
|
 |
|
|
|
|
 |
Y.H.Chiu,
M.Zhao,
and
Z.J.Chen
(2009).
Ubiquitin in NF-kappaB signaling.
|
| |
Chem Rev,
109,
1549-1560.
|
 |
|
|
|
|
 |
M.Y.Balakirev,
and
K.D.Wilkinson
(2008).
OTU takes the chains OUT.
|
| |
Nat Chem Biol,
4,
227-228.
|
 |
|
|
|
|
 |
S.C.Sun
(2008).
Deubiquitylation and regulation of the immune response.
|
| |
Nat Rev Immunol,
8,
501-511.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |